OBJECTIVE：To systematically review the effectiveness of high-dose atorvastatin in the prevention of cardiovascular events in patients with percutaneous coronary intervention（PCI）， and provide evidence-based reference for clinical treatment. METHODS： Retrieved from Medline，EMBase， Central，CJFD and Wanfang database， randomized controlled trials（RCT）of high- dose atorvastatin （test group） based on conventional treatment （control group） in the prevention of cardiovascular events in patients with PCI were collected. Meta-analysis was performed by using Rev Man 5.3 software after data extraction and quality evaluation with Cochrane 5.1.0 systematic reviewers manual. RESULTS：Totally 12 RCT were enrolled， involving 2 081 patients. Results of Meta-analysis showed， the incidence of myocardial infarction [OR＝0.55，95％CI（0.43，0.71），P＜0.001] and the main adverse cardiovascular events [OR＝0.58，95％CI（0.44，0.78），P＜0.001] in test group were significantly lower than control group， the differences were statistically significant. CONCLUSIONS： High-dose atorvastatin can effectively reduce the incidence of perioperative myocardial infarction and the main cardiovascular events in patients with PCI.